Resume
Researcher
Sami
El Khatib
Dean - School of Literarure & Sciences at The International University of Beirut
Biomedical Sciences Department
Citations
-
Contact Info
Resume
About
Dr. Sami El Khatib, Dean of the School of Literature & Sciences at the International University of Beirut (BIU), Holder of a Ph.D. in Cell Biology, a Master Degree in Bioengineering & Biomaterials, University Diploma in Animal Experimentation from France, and a BS in Medical Laboratory from Lebanese University. His research work was focused on the non-invasive techniques of diagnosis and treatment of Bladder Cancer, published in international peer-reviewed journals. He published the first work conducted in vivo for the usage of Hexvix as a prodrug for the Photodynamic treatment of bladder cancer in rats. He developed a reproducible model for solitary bladder cancer in rats used for many research and pharmacokinetics applications.
Research Experience
Professor (Associate)
Lebanese International University February 2006 - Present
Education
Henri Poincaré University
2002 - 2005
Doctoral Degree , Cell Biology & Oncology
Henri Poincaré University
2000 - 2001
Master's Degree , Bioengineering & Biomaterials
Lebanese University
1996 - 2000
Bachelor's Degree , Medical Laboratory
Presentations/Talks
Basics & Applications of Molecular Biotechnology i
Convention Center Parking in Abu Dhabi, United Arab Emirates Sep 2017
The Middle East Molecular Biology Society Conferen

Protein-based therapeutics are highly successful in clinic and currently enjoy unprecedented recognition of their potential. More than 100 genuine and similar number of modified therapeutic proteins are approved for clinical use in the European Union and the USA with 2010 sales of US$108 bln; monoclonal antibodies (mAbs) accounted for almost half (48%) of the sales. Based on their pharmacological activity, they can be divided into five groups: (a) replacing a protein that is deficient or abnormal; (b) augmenting an existing pathway; (c) providing a novel function or activity; (d) interfering with a molecule or organism; and (e) delivering other compounds or proteins, such as a radionuclide, cytotoxic drug, or effector proteins. Therapeutic proteins can also be grouped based on their molecular types that include antibody-based drugs, Fc fusion proteins, anticoagulants, blood factors, bone morphogenetic proteins, engineered protein scaffolds, enzymes, growth factors, hormones, interferons, interleukins, and thrombolytics. They can also be classified based on their molecular mechanism of activity as (a) binding non-covalently to target, e.g., mAbs; (b) affecting covalent bonds, e.g., enzymes; and (c) exerting activity without specific interactions, e.g., serum albumin. Most protein therapeutics currently on the market are recombinant and hundreds of them are in clinical trials for therapy of cancers, immune disorders, infections, and other diseases. New engineered proteins, including bispecific mAbs and multispecific fusion proteins, mAbs conjugated with small molecule drugs, and proteins with optimized pharmacokinetics, are currently under development. However, in the last several decades, there are no conceptually new methodological developments comparable, e.g., to genetic engineering leading to the development of recombinant therapeutic proteins. It appears that a paradigm change in methodologies and understanding of mechanisms is needed to overcome major challenges, including resistance to therapy, access to targets, complexity of biological systems, and individual variations.

Membership
Dr. Sami El Khatib
Jan 2017 - Permanent
Middle East Molecular Biology Society
Media Publications
Coronavirus - COVID-19
Lebanese International University | Jan , 2020
Coronavirus - COVID-19
Lebanese International University | Jan , 2020
Realted Researchers